Abstract
Despite benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with reduced ejection fraction (HFrEF), concerns for adverse events in patients (pts) with diabetes (DM) limit use. The characteristics and outcomes of DM pts receiving MRAs are not well characterized. We analyzed 1,
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
